Skip to main content

Trinity College Dublin, The University of Dublin

Trinity Menu Trinity Search

Trinity Research

Dr. Julie Kelly
Research Associate Professor, Clinical Medicine
Research Associate Professor, Trinity Inst. of Neurosciences (TCIN)

Publications and Further Research Outputs

Peer-Reviewed Publications

Kelly JA, Boyle NT, Cole N, Slator GR, Colivicchi MA, Stefanini C, Gobbo OL, Scalabrino GA, Ryan SM, Elamin M, Walsh C, Vajda A, Goggin MM, Campbell M, Mash DC, O'Mara SM, Brayden DJ, Callanan JJ, Tipton KF, Della Corte L, Hunter J, O'Boyle KM, Williams CH, Hardiman O, First-in-class thyrotropin-releasing hormone (TRH)-based compound binds to a pharmacologically distinct TRH receptor subtype in human brain and is effective in neurodegenerative models., Neuropharmacology, 89C, 2015, p193-203 Journal Article, 2015 TARA - Full Text DOI

Hogan N, O'Boyle KM, Hinkle PM, Kelly JA. , A novel TRH analog, Glp-Asn-Pro-d-Tyr-d-TrpNH2, binds to [3H][3-Me-His2]TRH-labelled sites in rat hippocampus and cortex but not pituitary or heterologous cells expressing TRHR1 or TRHR2., Neurosci Lett., 431, (1), 2008, p26-30. Journal Article, 2008 URL DOI

Campbell M, Kiang AS, Kenna PF, Kerskens C, Blau C, O'Dwyer L, Tivnan A, Kelly JA, Brankin B, Farrar GJ, Humphries P. , RNAi-mediated reversible opening of the blood-brain barrier. , Journal of Gene Medicine, 10, (8), 2008, p930 - 947 Journal Article, 2008

Scalabrino GA, Hogan N, O'Boyle KM, Slator GR, Gregg DJ, Fitchett, Discovery of a dual action first-in-class peptide that mimics, Neuropharmacology., 52, (7), 2007, p1472-81 Journal Article, 2007 DOI URL

Kelly JA, Scalabrino GA, Slator GR, Cullen AA, Gilmer JF, Lloyd DG, Bennett GW, Bauer K, Tipton KF, Williams CH., Structure-activity studies with high-affinity inhibitors of pyroglutamyl-peptidase II, Biochem J., 389, (Pt 2), 2005, p569 - 576 Journal Article, 2005

Kelly Julie A, Irish Patent Application, Compounds that modulate TRH actions, 2004, PCT/IE2005/000110 Patent, 2004

Kelly JA, Slator GR, O'Boyle KM., Pharmacological distinct binding sites in rat brain for [3H]-thyrotropin-releasing hormone (TRH) and [3H][3-methyl-histidine2]TRH, Biochem. Pharmacol., 63, (12), 2002, p2197 - 2206 Journal Article, 2002

Papadopoulos T, Kelly JA, Bauer K., Mutational analysis of the thyrotropin-releasing hormone-degrading ectoenzyme. Similarities and differences with other members of the M1 family of aminopeptidases and thermolysin, Biochemistry, 40, 2001, p9347 - 9355 Journal Article, 2001

Kelly Julie A, TRH-like peptide derivatives as inhibitors of the TRH-degrading ectoenzyme, 2000, PCT/IE01/00027; US 0030166944 Patent, 2000

Kelly JA, Slator GR, Tipton KF, Williams CH, Bauer K., Kinetic investigation of the specificity of porcine brain thyrotropin-releasing hormone-degrading ectoenzyme for thyrotropin-releasing hormone-like peptides, J. Biol. Chem., 275, (22), 2000, p16746 - 16751 Journal Article, 2000

Kelly JA, Slator GR, Tipton KF, Williams CH, Bauer K., Development of a continuous fluorometric coupled enzyme assay for thyrotropin-releasing hormone-degrading ectoenzyme, Anal. Biochem., 274, 1999, p195 - 202 Journal Article, 1999

Research Expertise

Description

The main focus of Dr Kelly's research relates to understanding the functions of thyrotropin-releasing hormone (TRH) in the central nervous system (CNS) and to enhancing its central therapeutic actions. Based on its central actions, TRH has significant potential in treating a variety of CNS disorders with unmet clinical need, including CNS trauma, spinocerebellar degeneration, epilepsy and depression. Critically, however, the clinical use of TRH and investigation of its CNS functions are hindered due to its rapid degradation. Dr Kelly is currently investigating the properties of novel compounds that may provide a means to reduce TRH degradation and thus may facilitate investigation of TRH actions in an experimental setting and may have potential medical application.

Projects

  • Title
    • Preclinical Evaluation of a Novel Neurotherapeutic for ALS
  • Summary
    • Principal Investigator
  • Funding Agency
    • Fondation Thierry Latran
  • Date From
    • 2011
  • Date To
    • 2012
  • Title
    • Determining beneficial effects of a new therapeutic compound, JAK4D, in the SOD1 mouse model of Amyotrophic Lateral Sclerosis (ALS)
  • Summary
    • €128,500 Principal Investigator
  • Funding Agency
    • Irish Motor Neurone Disease Research Foundation
  • Date From
    • 2009
  • Date To
    • 2011
  • Title
    • Development of a Novel Compound for treating Neurological Disorders.
  • Summary
    • €392,415 Principal Investigator (PI)
  • Funding Agency
    • Enterprise Ireland CFTD/2006/122
  • Date From
    • 2007
  • Date To
    • 2009
  • Title
    • Parenteral delivery system for first in class compound with potential therapeutic application in CNS disorders.
  • Summary
    • €85,025 (2006-2007) Principal Investigator (PI)
  • Funding Agency
    • Enterprise Ireland
  • Date From
    • 2006
  • Date To
    • 2007
  • Title
    • Furthering the development of potent thyrotropin-releasing hormone-degrading ectoenzyme (TRH-DE inhibitors - toward a novel therapeutic strategy for CNS disorders.
  • Summary
    • €238,703 (2005-2008) [Principal Investigator (PI)]
  • Funding Agency
    • HRB Project Grant RP/2005/152
  • Date From
    • 2005
  • Date To
    • 2008
  • Title
    • Exploration of methods to provide sustained expression of TRH peptide in a target tissue and investigation of neuroprotective properties of TRH.
  • Summary
    • €165,000 (2005-2008) with Dr G. J. Farrar (PI, TCD) and Professor C. O'Driscoll.
  • Title
    • Optimisation and characterisation of potent, selective thyrotropin-releasing hormone-degrading ectoenzyme (TRH-DE) inhibitors and investigation of their functional effects in the CNS
  • Summary
    • €421,805 (2000 -2004) PI
  • Funding Agency
    • Wellcome Trust Project Grant
  • Title
    • Exploiting chemical libraries, structural analysis and biological testing to design thyrotropin-releasing hormone-degrading ectoenzyme (TRH-DE) inhibitors for use in the treatment of CNS disorders.
  • Summary
    • HRB Inter-disciplinary Project Grant: €130,000. Co-PI with Prof. K. F. Tipton (TCD)
  • Funding Agency
    • HRB Inter-disciplinary Project Grant
  • Date From
    • 2002
  • Date To
    • 2004
  • Title
    • Exploration of ribozyme-based suppression of thyrotropin-releasing hormone-degrading ectoenzyme (TRH-DE) gene expression as a novel therapeutic approach for CNS injury.
  • Summary
    • HRB Project Grant: €112,500. Co-PI with Dr. G. J. Farrar
  • Funding Agency
    • HRB Project Grant
  • Date From
    • 2002
  • Date To
    • 2005
  • Title
    • Systematic study of structure-activity relationships for thyrotropin-releasing hormone (TRH) receptor ligands.
  • Summary
    • Enterprise Ireland Basic Research Grant: €126,800 with Dr. K. M. O'Boyle (PI, UCD)
  • Funding Agency
    • Enterprise Ireland Basic Research Grant
  • Date From
    • 2002
  • Date To
    • 2005
  • Title
    • Development of a Novel Compound for treating Neurological Disorders.
  • Summary
    • €392,415 (2007-2009) Principal Investigator (PI)
  • Funding Agency
    • Enterprise Ireland CFTD/2006/122
  • Date From
    • 2006
  • Title
    • Design and synthesis of inhibitors of thyrotropin-releasing hormone (TRH)-degrading ectoenzyme for use in assessing the role of this enzyme and TRH in the CNS.
  • Summary
    • €497,618. PI
  • Funding Agency
    • Wellcome Trust Re-Entry Fellowship
  • Date From
    • 1995
  • Date To
    • 2000

Recognition

Memberships

The Biochemical Society

American Chemical Society (ACS)

Royal Society of Chemistry (RCS)

International Society for Neurochemistry (ISN)

Sigma Xi

American Association for the Advancement of Science (AAAS)

Trinity Website Feedback